Alerta

COMPOSITIONS AND METHODS FOR TREATMENT OF SUBJECTS SUFFERING FROM A SARS-COV-2 INFECTION

Resumen de: US20260256871A1

0000 The application is directed to methods for treatment or prevention of SARS-CoV-2 infection in a subject in need thereof, the composition comprising an organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically acceptable salt thereof, and methods of using the same.

COVID-19 AND RESPIRATORY DISEASE VIRUS INFECTION MODELS USING LUNG ORGANOIDS

Resumen de: US20260259197A1

The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.

BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

Resumen de: US20260256905A1

0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

SARS-CoV-2 Fc Recombinant adenovirus comprising SARS-CoV-2 derived receptor binding domain and antibody Fc region and uses thereof

Resumen de: WO2026182475A1

The present invention relates to a recombinant adenovirus comprising a SARS-CoV-2-derived receptor-binding domain and an antibody Fc region, and a use thereof, and provides: a polynucleotide comprising a SARS-CoV-2 spike-derived receptor-binding domain and an antibody Fc region; a recombinant adenovirus comprising the polynucleotide; and a vaccine composition for preventing SARS-COV-2 infection, comprising the recombinant adenovirus as an active ingredient.

USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION

Resumen de: EP4799624A2

Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications associated with RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising Pipendoxifene or analogues thereof (e.g., a compound of Formula (I), Formula (II), or Formula (III)) to a patient in need. One or more additional therapeutic agents can also be administered to the patient in the disclosed methods.

COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19

Resumen de: WO2025090605A1

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAME

Resumen de: WO2023209177A1

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.

Nouveaux composés à base d’acides aminés modifiés comme inhibiteurs de la réplication du SARS-CoV-2, leurs formulations et applications

Resumen de: MA70856A1

Cette invention est relative à de nouveaux composés à base de lacide éthacrynique couplé avec des acides aminés modifiés comme lillustre la formule (I). Ces composés sont conçus pour le traitement du SARS-CoV-2, des pathologies liées à la COVID-19, ainsi que des maladies associées aux -coronavirus. Cette invention porte également sur leur application in vitro pour étudier l'inhibition de la réplication du SARS CoV2. De plus, cette invention inclut des compositions pharmaceutiques comprenant, comme principe actif, au moins un composé de la formule (I).

Methods and modified nucleosides for treating coronavirus infections

Resumen de: NZ802021A

Provided are methods for treating coronavirus infections by administering modified nucleosides, ester and amino acid ester prodrugs of nucleoside, their pharmaceutically acceptable salts, and drug combination thereof, of Formula (I). The compounds, combination, and methods provided are particularly useful for preventing, mitigating, or treating coronavirus infections or cytopathic effects resulting from the replication or reproduction of coronaviruses and their variants, including SARS-CoV-2.

Treatment of pathological fatigue with oxaloacetate

Resumen de: NZ801710A

The present disclosure relates to methods of treatment and compositions for treatment of Pathological Fatigue caused by injury or disease in the body. Pathological fatigue refers to physical and mental fatigue that is caused by viral infection, bacterial infection, trauma, disease, or genetic alteration that results in fatigue that is not improved by bed rest and may be worsened by physical or mental activity. Such pathologic fatigue occurs in myalgic encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) and other disorders such as such as post-COVID-19 fatigue, post-viral fatigue, fibromyalgia (FM), cancer, Parkinson’s Disease, other diseases and trauma as well as of combinations thereof. Related treatment methods and pharmaceutical compositions are also disclosed.

SARS-CoV-2 ANTIBODIES AND BISPECIFIC ANTIBODIES

Resumen de: US20260250363A1

0000 Provided herein are antibodies or antigen binding fragments thereof having a binding specificity for SARS-CoV-2 spike protein, and bispecific antibodies comprising a first and a second antigen binding region that bind to SARS-CoV-2 spike protein. Also provided herein are pharmaceutical compositions comprising the antibodies, antigen binding fragments thereof, or bispecific antibodies.

RECOMBINANT HPV16 E6E7 ADENOVIRUS, VACCINE THEREOF, METHOD FOR PREPARING SAME, AND USE THEREOF

Resumen de: WO2026174523A1

The present invention relates to the field of cancer immunotherapy technology, and specifically, to a recombinant HPV16 E6E7 adenovirus, a vaccine thereof, a method for preparing same, and use thereof. The present invention provides a recombinant HPV16 E6E7 adenovirus, comprising an HPV16 E6E7 antigen sequence and SARS-CoV-2 virus HR1 and HR2 region sequences. The recombinant HPV16 E6E7 adenovirus vaccine prepared by using the adenovirus, when used either alone or in combination with other anti-tumor drugs, can significantly inhibit the growth of tumors in cervical cancer and head and neck squamous cell carcinoma, and induce a significant cellular immune response in mice.

FUSION PROTEIN OF ULTRA-STABLE INTRACELLULAR ANTIBODY TARGETING PDIA3 AND USE THEREOF

Resumen de: WO2026175420A1

Provided are a fusion protein of an ultra-stable intracellular antibody targeting PDIA3 and the use thereof. The fusion protein comprises an antigen-binding peptide targeting PDIA3 and an intracellular stabilizing peptide. The antigen-binding peptide comprises a heavy chain variable region and a light chain variable region. By means of optimally designed intracellular stabilizing peptide and signal peptide sequences, the antibody can stably exist in cells and specifically localize to the endoplasmic reticulum. The fusion protein can effectively target and bind to the PDIA3 protein, significantly inhibit the expression levels of S proteins from human coronaviruses and capsid proteins from various non-enveloped viruses in cells, and regulate endoplasmic reticulum stress via protein-protein interactions on the ER of host cells, thereby promoting the degradation of the viral proteins and further effectively reducing the infectivity of the viruses.

MICRONEEDLE ARRAY PATCH FOR EXPRESSION OF THERAPEUTICS

Resumen de: WO2026178292A1

Microneedle patches or microneedle array patches (MAPs) offer a convenient method to intradermally deliver drugs and vaccines. Embodiments include MAPs that overcome the limitations of conventional MAPs. In aspects, the MAPs include (a) a base, (b) an adhesive region and (c) a plurality of needles on a surface of the base. The needles can comprise a medicament (e.g., a therapeutic or vaccine). In aspects, the medicament is a circular RNA vaccine that elicits an immune response against SARSCoV-2.

MULTI-PATCH VACCINES AND IMMUNOGENIC COMPOSITIONS, METHODS OF PRODUCTION AND USES THEREOF

Resumen de: US20260250326A1

0000 The present invention relates to a method for producing immunogenic compositions, such as vaccines, by identifying amino acid sequence of antigenic patches (Ag-Patches) from at least one proteome of a pathogen, derived from overlapping epitope clusters. In particular, the invention relates to the design of Multi-Patch Vaccines against viral, such as SARS-CoV-2, bacterial, fungi, parasite, pathogenic and non-pathogenic targets.

METHOD FOR TESTING DISEASED STATE OF VASCULITIS OR AGGRAVATION RISK OF COVID-19, TESTING KIT, COMPANION DIAGNOSTIC AGENT, AND TESTING MARKER

Resumen de: US20260251661A1

A method for testing a diseased state of vasculitis and a method for testing an exacerbation risk of COVID-19, the method including: detecting or quantifying, in a blood sample collected from a subject, (1) a No. 1 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 23 to 25 kDa, and/or (2) a No. 2 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 16 to 20 kDa.

DEVICES AND RELATED METHODS FOR VENTILATION

Resumen de: EP4796155A2

Provided herein are devices and methods that relate to ventilation and respiration. In one embodiment, a ventilator device comprising a fluidic amplifier with one or more coaxially aligned components, where there are no internal moving components. In another embodiment, a device and related methods for treating a patient who needs ventilation such as after infection by the coronavirus Covid-19.

METHOD FOR OBTAINING ETHYL 2-{2-(5-BENZYL-1,3,4-OXADIAZOLE-2-YL)SULFANYLACETAMIDE}-4H,5H,6H-CYCLOPENTAbTHIOPHENE-3-CARBOXYLATE, WHICH EXHIBITS PREDICTED ACTIVITY AGAINST THE SARS-CoV-2 VIRUS

Resumen de: UA164073U

Method for obtaining ethyl 2-{2-(5-benzyl-1,3,4-oxadiazole-2-yl)sulfanylacetamide}-4H,5H,6H-cyclopentabthiophene-3-carboxylate, which exhibits predicted activity against the SARS-CoV-2 virus, wherein mixture of equimolar amounts of 5-benzyl-1,3,4-oxadiazole-2-thiol and ethyl ester of 2-(2-chloro-acetylamino)-5,6-dihydro-4H-cyclopentabthiophene-3-carboxylic acid is boiled in the presence of calcined K₂CO₃ under a reflux condenser for two hours in acetonitrile, while stirring. Mixture is then cooled, poured into ice water, precipitate is filtered, dried, and recrystallized from 2-propanol.

KYNURENINE: USEFUL BIOMARKER IN ACUTE COVID-19 AND LONG COVID

Resumen de: EP4266057A1

The invention relates to an in vitro method for the detection of inflammation caused by an acute COVID-19 infection, long COVID and/or PIMS, wherein the level of kynurenine in a body fluid is determined and wherein the value of kynurenine measured in the patient to be diagnosed is compared with the average value obtained from a comparable cohort of persons who do not suffer from said diseases, whereby the value of kynurenine in patients is increased.

Antiviral cyclic compounds

Resumen de: US20260242415A1

0000 The present invention relates to novel cyclic peptides. The peptides bind viral proteins, particularly a conserved site on the SARS-CoV-2 spike protein, and therefore the peptides can be useful for neutralizing SARS-CoV-2 variants. Accordingly, the invention also relates to medical use of the peptides.

BROAD-SPECTRUM BISPECIFIC ANTIBODY AGAINST NOVEL CORONAVIRUSES

Resumen de: US20260242448A1

The present disclosure provides a broad-spectrum bispecific antibody against novel coronaviruses, comprising a first targeting domain D1 targeting a first epitope of a SARS-CoV-2 RBD domain, and a second targeting domain D2 targeting a second epitope of the SARS-CoV-2 RBD domain. The bispecific antibody of the present disclosure has a broad-spectrum neutralizing activity and can effectively neutralize SARS-CoV-2 and various highly infectious and harmful SARS-CoV-2 variant strains, thus showing significant application value in the prevention, treatment, and/or detection of infections caused by novel coronaviruses.

ANTIVIRUS PROTEINS HAVING A KRINGLE 5 SUBUNIT

Resumen de: US20260242447A1

COVID-19 results from the infection of the SARS-CoV-2 virus and has spread quickly to literally infected the world. Although coronavirus spike proteins can recognize a broad range of host cell-surface proteins, inhibiting spike protein binding to a survival factor called GRP78 results in a significant reduction in SARS-CoV-2 attachment, entry and replication in lung and kidney cells. This inhibition is accomplished with a novel type of inhibitor that potently blocks the binding of SARS-CoV-2 spike protein and whole virus to surface-bound GRP78. These novel GRP78 inhibitors also down regulate cytokines (IL10, IL6), immune co-inhibitory checkpoint proteins (PD-L1, B7H3, B7H4), and up regulate immune co-stimulatory proteins (MHC-II, CD-86) resulting in the reduction of the immune suppressive nature of infected lung alveolar epithelial cells in vitro and in vivo. Finally, these novel GRP78 inhibitors inhibit the hyperfibrinolysis of infected lung cells by reducing the activation of plasmin on cell surfaces.

NOVEL CORONAVIRUS PROTECTIVE NASAL SPRAY, AND PREPARATION AND USE THEREOF

Resumen de: US20260242763A1

0000 A fully human ACE2-Fc fusion protein, a pharmaceutical composition, preparation and kit containing same, and a nasal spray containing the fusion protein. Also provided is a use of the fusion protein for broad-spectrum prevention of coronavirus infections, such as infections with coronavirus SARS-CoV-2 and known and unknown variants thereof, including but not limited to original Hu-1, alpha, beta, gamma, delta, mu, omicron, JN.1, and/or other future strains. Also provided are a method for producing the fusion protein, and a method for using the fusion protein to prevent and/or treat infections with coronavirus SARS-CoV-2 and known and unknown variant strains thereof. Further provided is a use of the fusion protein and the pharmaceutical composition and preparation containing same for preventing the spread of coronavirus SARS-CoV-2 and known and unknown variant strains in infected subjects.

BENZODIAZOCINE COMPOUND AS ANTIVIRAL AGENT AND PROCESS FOR PREPARATION THEREOF

Resumen de: WO2026172365A1

This study presents the synthesis of novel Benzodiazocine analogues and their potential as potent antiviral agents. Benzodiazocines, featuring an eight-membered fused bicyclic core, adhere to Lipinski's rule of five, ensuring drug-like properties. Structural modifications via Structure-Activity Relationship (SAR) enhanced their antiviral efficacy. In vitro assays, including cytotoxicity analysis and RT-qPCR-based studies, evaluated activity against SARS- CoV-2. Several analogues demonstrated promising antiviral potential, contributing to the ongoing pursuit of effective therapeutics against viral infections.

USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-COV-2

Nº publicación: US20260240794A1 20/08/2026

Solicitante:

CHRONIC AIRWAY THERAPEUTICS LTD [AU]
Chronic Airway Therapeutics Limited

Resumen de: US20260240794A1

The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.